Cano Health (CANO) Misses Q4 EPS by 49c; Offers FY23 Revenue Guidance

Cano Health (NYSE: CANO) reported Q4 EPS of ($0.61), $0.49 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $680.37 million versus the consensus estimate of $651.64 million.

GUIDANCE:

Cano Health sees FY2023 revenue of $3.1-3.25 billion, versus the consensus of $3.26 billion.

For earnings history and earnings-related data on Cano Health (CANO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c